RODMAN&RENSHAW upgraded shares of Indivior (NASDAQ:INDV - Free Report) to a strong-buy rating in a report published on Tuesday,Zacks.com reports.
INDV has been the subject of a number of other research reports. Craig Hallum decreased their price target on Indivior from $20.00 to $16.00 and set a "buy" rating for the company in a report on Friday, October 11th. Piper Sandler reissued an "overweight" rating and set a $16.00 target price (up from $15.00) on shares of Indivior in a research report on Friday, October 25th. Finally, Rodman & Renshaw assumed coverage on shares of Indivior in a report on Tuesday. They set a "buy" rating and a $16.00 price target for the company.
Get Our Latest Report on Indivior
Indivior Stock Down 2.5 %
Shares of NASDAQ INDV traded down $0.30 on Tuesday, hitting $11.90. The company had a trading volume of 830,064 shares, compared to its average volume of 1,062,511. Indivior has a 12-month low of $7.33 and a 12-month high of $23.22. The firm has a market capitalization of $1.64 billion, a P/E ratio of -297.43 and a beta of 0.74. The business has a 50 day moving average of $11.80 and a two-hundred day moving average of $11.04.
Institutional Investors Weigh In On Indivior
Hedge funds and other institutional investors have recently bought and sold shares of the business. Iron Triangle Partners LP acquired a new stake in shares of Indivior during the third quarter worth approximately $8,243,000. Krensavage Asset Management LLC bought a new position in Indivior during the 3rd quarter valued at $6,843,000. Stonepine Capital Management LLC acquired a new position in Indivior during the 3rd quarter worth $2,632,000. Clark Estates Inc. NY acquired a new position in Indivior in the third quarter worth about $2,477,000. Finally, AlphaCentric Advisors LLC bought a new stake in shares of Indivior in the 3rd quarter valued at approximately $2,364,000. 60.33% of the stock is currently owned by hedge funds and other institutional investors.
Indivior Company Profile
(
Get Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Recommended Stories
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
